Zhong Zhao
Chief Executive Officer chez ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD.
Fortune : 120 M $ au 31/03/2024
Profil
Zhong Zhao is the founder of Zylox-Tonbridge Medical Technology Co., Ltd.
where he currently holds the title of Chairman & Chief Executive Director since 2012.
He is also currently working as an Independent Director at Avinger, Inc. since 2024.
Previously, Dr. Zhao worked as an Associate Director at Guilford Pharmaceuticals, Inc. from 1996 to 2002 and as a Principal Scientist at Cordis Corp.
from 2002 to 2011.
He obtained his doctorate degree from The Johns Hopkins University School of Medicine in 1997.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 05/04/2024 | 88 860 231 ( 27,37% ) | 110 M $ | 31/03/2024 | |
| 30/06/2023 | 8 020 684 ( 103,08% ) | 10 M $ | 31/03/2024 | |
AVINGER, INC.
4,43% | 05/03/2024 | 75 327 ( 4,43% ) | 233 438 $ | 31/03/2024 |
Postes actifs de Zhong Zhao
| Sociétés | Poste | Début |
|---|---|---|
| ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD. | Chief Executive Officer | 06/11/2012 |
| AVINGER, INC. | Director/Board Member | 05/03/2024 |
Anciens postes connus de Zhong Zhao
| Sociétés | Poste | Fin |
|---|---|---|
Cordis Corp.
 Cordis Corp. Medical SpecialtiesHealth Technology Cordis Corp. develops and manufactures devices for interventional vascular medicine and electrophysiology. The firm's products include guidewires, balloons, forceps, catheters, and stents to treat a variety of circulatory system problems including coronary artery disease and cerebral aneurysms. The company was founded by William P. Murphy Jr. in 1959 and is headquartered in Milpitas, CA. | Corporate Officer/Principal | 01/08/2011 |
Guilford Pharmaceuticals, Inc.
 Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Corporate Officer/Principal | 01/06/2002 |
Formation de Zhong Zhao
| The Johns Hopkins University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Cordis Corp.
Cordis Corp. Medical SpecialtiesHealth Technology Cordis Corp. develops and manufactures devices for interventional vascular medicine and electrophysiology. The firm's products include guidewires, balloons, forceps, catheters, and stents to treat a variety of circulatory system problems including coronary artery disease and cerebral aneurysms. The company was founded by William P. Murphy Jr. in 1959 and is headquartered in Milpitas, CA. | Health Technology |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Health Technology |
| Avinger, Inc. |
